Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating ...

Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its manufacturing presence in the Tar Heel state. But that’s not enough for the ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives ...

Biogen is acquiring Apellis Pharmaceuticals in a $5.6 billion deal that brings two FDA-approved products commercialized in four indications, all of which are expected to contribute to the revenue ...

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...